DJIA 17,039.49 60.36 0.36%
NASDAQ 4,532.10 5.62 0.12%
S&P 500 1,992.37 5.86 0.29%
market minute promo


company name or ticker

Why Orexigen Therapeutics is Falling Today

Orexigen Therapeutics announced today that the regulatory decision for its obesity medication Contrave will be delayed by three months, causing shares to crater in early trading. Are investors overreacting?

Down 18%: Is Orexigen a Bad News Buy?

The stock cratered 18% on a delayed FDA decision...but was the sell-off overdone?

Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

FDA Delays Decision On Orexigen Anti-Obesity Drug - What This Means To The Stock

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

Orexigen's Date With Destiny

Orexigen's Contrave should be approved this week, but will it be able to perform better than obesity drugs from Arena Pharmaceuticals and VIVUS?

Orexigen Investors Hope For FDA Approval

Orexigen Could Be A Double-Edged Sword For Arena

Is Vivus About To Get Squeezed?

As Orexigen Faces FDA Will Weight Loss Landscape Change?

As Orexigen once again faces FDA approval, it appears as though the landscape for weight loss drugs may once again change.
See More Articles...